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Abstract
Background: Anderson-Fabry disease (FD) is caused by a deficit of the a-galactosidase A enzyme which leads to
the accumulation of complex sphingolipids, especially globotriaosylceramide (Gb3), in all the cells of the body,
causing the onset of a multi-systemic disease with poor prognosis in adulthood. In this article, we describe two
alternative methods for screening the GLA gene which codes for the a-galactosidase A enzyme in subjects with
probable FD in order to test analysis strategies which include or rely on initial pre-screening.
Findings: We analyzed 740 samples using EcoTILLING, comparing two mismatch-specificendonucleases, CEL I and
ENDO-1, while conducting a parallel screening of the same samples using HRM (High Resolution Melting).
Afterwards, all samples were subjected to direct sequencing. Overall, we identified 12 different genetic variations:
-10C>T, -12G>A, -30G>A, IVS2-76_80del5, D165H, C172Y, IVS4+16A>G, IVS4 +68 A>G, c.718_719delAA, D313Y, IVS6-
22C>T, G395A. This was consistent with the high genetic heterogeneity found in FD patients and carriers. All of the
mutations were detected by HRM, whereas 17% of the mutations were not found by EcoTILLING. The results
obtained by EcoTILLING comparing the CEL I and ENDO-1 endonucleases were perfectly overlapping.
Conclusion: On the basis of its simplicity, flexibility, repeatability, and sensitivity, we believe thatHRM analysis of
the GLA gene is a reliable presequencing screening tool. This method can be applied to any genomic feature to
identify known and unknown genetic alterations, and it is ideal for conducting screening and population studies.
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Introduction
Fabry disease (FD) is a lysosomal storage disease caused by
a congenital error in glycosphingolipid metabolism result-
ing from the deficient or absent activity of the lysosomal
enzyme a-galactosidase A [1]. This enzyme is essential for
the sphingolipid recycling process that occurs within cells.
It is able to remove the galactose bound in the alpha posi-
tion in complex sphingolipids, allowing their metabolism.
The enzyme deficiency causes the interruption of the pro-
cess of waste product demolition, leading to the intracellu-
lar accumulation of complex sphingolipids, especially
globotriaosylceramide (Gb3) [2]. The accumulation of
these products is the basis of FD symptomology that
includes acroparesthesias, angiokeratoma, corneal and
lenticular opacities, gastrointestinal problems and diseases
of the kidney, heart and central nervous system [3-5]. The
GLA gene (12 kb) contains seven exons (92 to 291 bp), is
located on the X chromosome, and encodes a polypeptide
of 429 amino acids [6].
In the literature, more than 500 mutations in the GLA
gene have been associated with FD [7]. Of these, only 5%
are localized in exons and are able to cause the formation
of a truncated protein. Instead, for the most part, they
involve missense mutations generating null alleles or
changes in specific domains of the protein; others, such
as those that occur in splicing sites, can lead to aberrant
splicing and can be responsible for altered forms of the
enzyme [8,9]. Polymorphisms, small deletions, and inser-
tions in the GLA gene have been detected by direct
sequencing [10], through single-strand conformation
polymorphism analysis [11], and by denaturing high
performance liquid chromatography (DHPLC) [12].
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any medium, provided the original work is properly cited.However, these investigative techniques may be limited in
the analysis of large numbers of samples, so it is therefore
necessary to move towards new analytical approaches
which include or rely on pre-screening.
In our study, we performed genetic analyses of the GLA
gene in 740 subjects with symptoms related to FD using
two different approaches to genetic screening. The first
was a method based on the enzymatic cleavage of mis-
matches, known by the acronym EcoTILLING (Targeting
Induced Local Lesions in Genomes), originally used for
studying the plant genome and adapted to researching
human genetic variations [13]. We conducted these ana-
lyses using a screening strategy based on pools of 8 sam-
ples using two mismatch-specific endonucleases, CEL I
(SURVEYOR Mutation Detection Kit-Transgenomic) and
ENDO-1 (Serialgenetic). The second method was based
on HRM which is able to detect genetic mutations based
on the dissociation temperature of the two strands (Tm)
and the analysis of the melting curves (LightCycler480,
Roche)[14]. We applied these techniques to analyze the
coding regions and intron junction regions of the GLA
gene in order to investigate mutations in the coding
regions and splicing regulatory sites. Finally, to verify the
results obtained, each sample was analyzed by direct
sequencing.
Materials and methods
DNA extraction and quantification
DNA was extracted by column extraction (GenElute
Blood Genomic DNA Kit, Miniprep - Sigma Aldrich)
from 740 peripheral blood samples of subjects with clin-
ical manifestations related to FD symptomatology. The
study was approved by University Hospital Ethics Com-
mittee and written informed consent was obtained from
all participants.
The concentration of the DNA was determined by spec-
trophotometer (Victor X3 - PerkinElmer), and the concen-
tration was adjusted to 100 ng/microliter in TE (10 mM
Tris-HCl and 1 mM EDTA, pH 7.4) or water.
Primer design
Seven pairs of primers were designed for the analyses of
the seven target regions containing the seven exons of the
GLA gene and the splicing regulatory regions flanking
them, and they were obtained using the GeneTools pro-
gram. The gene sequence was obtained from the site
http://www.ensembl.org (ENSG00000102393). The pri-
mers used for the EcoTILLING and HRM analyses were
identical but for marking with IRDye700 in forward and
IRDye800 in reverse (Table 1).
EcoTILLING pooling
For the simultaneous analysis of a large number of sam-
ples, we chose a strategy of pooling, as described by
Till et al. [15]. For a high-throughput screening, the
740 DNA samples were divided into groups of 64 sam-
ples each, arranged in 8 × 8 grids and then assembled in
pools of 8 samples (Figure 1). Each pool was obtained
by adding all the samples present in a row or column of
the grid, repeating the procedure for the 8 rows and 8
columns of each grid. The 16 pools derived from each
grid were arranged in a second plate and subjected to
the EcoTILLING method. The presence of the frag-
ments in two pools containing the same sample allowed
us to trace the exact location of the sample in the grid
and then to identify the subject.
Each PCR was performed in a final volume of 50 μl( H o t
Start Master Mix - GE Healthcare) with 1 μM of primers,
50 ng of DNA. The amplification was performed using
the following parameters: 95°C for 2 minutes, 40 cycles
with 95°C for 30 minutes, 58°C for 30 minutes, 72°C for
1 minute, and a final extension at 72°C for 10 minutes.
Mixing 8 different samples ensures the formation of a
heteroduplex in the presence of a mutation. The samples
thus obtained were denatured and renaturated according
to the following parameters: 95°C for 2 minutes, followed
by a decrease in temperature of 0.5°C for 15 minutes, until
45°C. The heteroduplexes were subjected to enzymatic
digestion by the endonucleases CEL I (SURVEYOR Muta-
tion Detection Kit - Transgenomic) and, in parallel,
ENDO-1 (Serialgenetics). The reaction was incubated at
42°C for 20 minutes and stopped by adding 1.5 μls t o p
buffer, or at 37°C for 40 minutes and stopped with 5 μl
stop buffer, respectively. All reagents were supplied by the
Surveyor kit (SURVEYOR Mutation Detection Kit -
Transgenomic) and by the ENDO-1 Endonuclease Kit
(Serialgenetics).
Electrophoretic Separation
The fragments were separated by electrophoretic migra-
tion (DNAanalyzer 4300 - Licor) on polyacrylamide gel
(KB-plus 6.5% gel-matrix - Licor). The scanning of gels
subjected to electrophoresis permits the detection of the
presence of mutations and their location in the analyzed
fragment, deduced on the basis of the size of the frag-
ments obtained. The gels were analyzed using the Gel-
Buddy program in manual mode.
PCR-High Resolution Melting (HRM)
Genetic screening for the presence of mutations in the
GLA gene was conducted by Real-Time PCR and subse-
quent HRM (Figure 2). The PCR was carried out on a final
volume of 20 μl, according to the following amplification
program: 95°C for 10’ minutes, 50 cycles at 95°C for
10 minutes, 62°C for 15 minutes, 72°C for 18 minutes. The
amplification in Real-Time PCR and the dissociation of the
two DNA strands were performed in the presence of a
fluorescent marker (Light Cycler
® 480 High Resolution
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method, male subjects were analyzed by adding a wild type
DNA counterpart, in a 1:1 volume ratio.
Sequencing
To test the reliability of the results obtained, all samples
were subjected to direct sequencing according to the
following program: 94°C for 2 minutes, 30 cycles at 96°




The need to perform simultaneous analyses of many
samples led to the adoption of a high-throughput screen-
ing strategy based on pools of 8 samples, as reported by
Till et al. [15]. In this study, we have carried out genetic
screening of the seven chosen target regions for the
analysis of the GLA gene on 740 samples (Figure 3). The
analysis was done by comparing two enzymes with endo-
nuclease activity (ENDO-1 and CEL I), and their recogni-
tion efficiency and heteroduplex cut fragments were
identical. The mutations and polymorphisms identified
by EcoTILLING are shown in Table 2.
High Resolution Melting
In order to evaluate the results obtained by EcoTIL-
LING, we conducted another screening with High Reso-
lution Melting. The ten mutations/polymorphisms
identified by EcoTILLING were confirmed, and two
further gene variations (G395A; IVS6-22c>t), undetected
by enzymatic digestion by the CEL I and ENDO-1 endo-
nucleases, were identified (Table 3). The mutations
which were undetected by EcoTILLING were analyzed
Table 1 The seven primer pairs used for HRM analyses and the corresponding amplification fragments
Region Primers Amplicon sizes Exon sizes MgCl2 conc.
Exon 1 5’-TCTTACGTGACTGATTATTGGTCT-3’
5’-CACACCCAAACACATGGAAA-3’
416 bp 254 bp 3.5 mM
Exon 2 5’-TGAAATCCCAAGGTGCCTAATA-3’
5’-GTACAGAAGTGCTTACAGTCC-3’
314 bp 174 bp 3.5 mM
Exon 3 5’-ACCTGGTGAAGTAACCTT-3’
5’-CTCAGCTACCATGGCCT-3’
349 bp 178 bp 3.5 mM
Exon 4 5’-GCTGGAAATTCATTTCTTTCCC-3’
5’-GGATGGTGAGAAGTGGTTG-3’
285 bp 91 bp 3.5 mM
Exon 5 5’-AATCTGTAAACTCAAGAGAAGGCTA-3’
5’-CTTTACCTGTATTTACCTTGAATG-3’
349 bp 161 bp 3.5 mM
Exon 6 5’-GATGCTGTGGAAAGTGGTT-3’
5’-GCCCAAGACAAAGTTGGTAT-3’
355 bp 198 bp 3 mM
Exon 7 5’-AGAATGAATGCCAAACTAAC-3’
5’-ATGAGCCACCTAGCCTTG-3’
443 bp 295 bp 3.5 mM
The primers used in the EcoTILLING protocol were identical and differentiated by their marking with IRDye700 and IRDye800 in forward and reverse, respectively.
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Figure 1 Diagram of sample pooling - (A) For the pooling strategy, 64 samples were first allocated in an 8 × 8 grid and then mixed in
pools of 8 samples each. (B) The 16 pools obtained were arranged in a second plate and subjected to the EcoTILLING protocol. After
enzymatic digestion, the identification of the pools with the same fragments permits the identification of the presence of heterozygotes and to
go back to the coordinates that identify the mutated sample.
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in the enzymatic digestion times or changes in analysis
of the relationship between mutated and wild type sam-
ples in the pool (Figure 4).
After direct sequencing of the 740 samples, no dis-
crepancies were found in the HRM results (Table 4).
According to the data, this technique appears to be the
optimal method for pre-sequencing screening of the
GLA gene. Indeed, the robustness of this method
ensures the identification of all possible genomic
variants.
Conclusions
The use of a screening system permits the identification of
samples to be subjected to sequencing, the performance of
the simultaneous analysis of numerous genetic traits, and
the undertaking of population studies.
EcoTILLING technology is recognized by the scientific
community as a method for the identification and charac-
terization of single nucleotide polymorphisms (SNPs) and
small and large deletions (indels) [16-18]. In this study we
analyzed pools of eight samples to reduce screening time
and/or the cost associated with the analysis of 740 sam-
ples, identifying ten genetic variants across the seven
exons and their flanking regions of the GLA gene. After
HRM analysis, we discovered two other previously unde-
tected mutations.
The detection of mutations with EcoTILLING shows a
number of disadvantages that limit its use in analyses of
human genetic diseases and in clinical medicine investiga-
tions. In particular, mismatch recognition sensitivity is
reduced when mutations are present at the ends of the
target sequence [15,19-23] and as the number of poly-
morphisms identified for each fragment increases.
(A)    (B) 
Figure 2 Amplification curves - (A) Amplification curves with characteristic sigmoid pattern. (B) Cycles of amplification, with the moments of
data acquisition by the CCD camera indicated in green. The area highlighted by a solid green line represents the dissociation phase of the strands.
A)                                                                               B) 
Figure 3 Pooling strategy for Exon 1 of the GLA gene - The 16 lines represent the 16 pools obtained through the pooling strategy for
rows (1R-8R) and columns (1C-8C). Above, PCR products undigested at 390bp, visible in both detection channels. (A) Images obtained in the
700 nm channel for the identification of fragments marked by the forward-IRDye700 primer. (B) Images obtained in the 800nm channel for the
identification of fragments marked by the reverse-IRDye800 primer. The 6R and 7C pools show fragment sizes of approximately 135 bp,
indicated by blue arrows (for IRDye 700), and 255 bp, indicated by red arrows (for IRDye 800). Sizes of the digested fragments indicate the
position of the mutation within the amplicon, and their sum comprises the dimensions of the undigested 390 bp fragment.
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dependent on the location and number of mutations pre-
sent in the analyzed fragment, but only on changes in the
dissociation kinetics of the amplified fragments with
respect to the wild type [24-27]. Because of its high relia-
bility and flexibility, it is currently employed as a method
of genotyping in clinical and diagnostic settings [28,29].
In genetics, this method has been applied to BRCA1/2
hereditary breast cancer [30], cystic fibrosis [31], haemo-
philia [32], the instability of microsatellites [33], the rear-
rangement of heavy chain genes in lymphomas [34], the
prenatal diagnosis of B-thalassaemia [35], analysis of
DNA methylation [36], the identification of bacterial spe-
cies [37,38], and other applications. Considering the poly-
morphic nature of the GLA gene, we sustain that HRM
analysis appears to be an ideal investigative tool which
permits the search for all possible gene variations with a
high level of reliability.
Finally, in the cases reported, some mutations seemed to
occur in haplotype patterns, as studies of genealogical
trees of the proband families confirmed. Indeed, 12% of
the subjects analyzed showed polymorphisms in the pro-
moter region of the GLA gene and, of these, 99% exhibited
several simultaneous polymorphisms spread throughout
the gene. In particular, the -10 c>t, IVS2-76_80 del5,
IVS4-16 A>G, IVS6-22C>T and -12 g>a, IVS4+68 A>G,
IVS6-22C>T polymorphisms occured simultaneously in
8.9% and 3.7% of the subjects, and the significance of this
haplotype in FD pathology remains unknown. In a pilot
study of patients with small fiber neuropathy of unknown
etiology, published in August 2010, Tanislav et al. reported
the presence of a complex intronic haplotype within the
Table 2 Diagram of the identified genetic variations after enzymatic digestion with CEL I and ENDO-1 and their
location
Region 1 Region 2 Region 3 Region 4 Region 5 Region 6 Region 7
Exon 1 Exon 2 Exon 3 Exon 4 Exon 5 Exon 6 Exon 7
Haplotype 1 -10 C>T wt IVS2 - 76_80del5 wt IVS4
-16A>G
wt wt
Haplotype 2 Polymorphism wt wt IVS2 - 76_80del5 wt IVS4
-16A>G
wt wt
Haplotype 3 -12G>A wt wt IVS4
+68A>G
wt wt wt
-10 C>T wt wt wt wt wt wt
Mutations -30G>A wt wt wt wt wt wt
wt wt C172Y wt wt wt wt
wt wt wt wt wt D313Y wt
wt wt wt wt wt wt wt
wt wt wt wt c.718_9 dellAA wt wt
wt wt D165H wt wt wt wt
Table 3 List of genetic variants found in the samples analyzed by enzymatic digestion using the CEL I or ENDO-1
endonuclease and by High Resolution Melting
Variation EcoTILLING (CelI or EndoI) HRM
Region 1 -10 c>t yes yes
-12 g>a yes yes
-30 g>a yes yes
Region 2 IVS2-76_80 del5 yes yes
Region 3 D165H yes yes
C172Y yes yes
Region 4 IVS4+68 A>G yes yes
Region 5 IVS4-16 A>G yes yes
c.718_719 del AA yes yes
Region 6 D313Y yes yes
Region 7 IVS6-22 C>T no yes
G395A no yes
The G395A mutation and the IVS6-22C>T polymorphism, identified exclusively through HRM, are shown in bold.
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Figure 4 EcoTILLING screening - Figure shows images related to the EcoTILLING screening conducted on 68 samples amplified with
the primer pair for Region 7. EcoTILLING analysis did not report the presence of some mutated samples (1) which were identified through
HRM (2) and confirmed by sequencing (3). (4) EcoTILLING experiments done by varying the digestion time or the number of samples per pool
did not change the results. a) Digestion times for pools with CEL I or ENDO-1. Lane 1: 15’; lane 2: 20’; lane3: 30’. Images of a single detection
channel. b) Proportion variations between mutated samples and wild type.
Table 4 Diagram of the genetic variations identified after HRM and their location.
Region 1 Region 2 Region 3 Region 4 Region 5 Region 6 Region 7
Exon 1 Exon 2 Exon 3 Exon 4 Exon 5 Exon 6 Exon 7
Haplotype 1 -10 C>T wt IVS2 - 76_80del5 wt IVS4 -16A>G wt IVS6 -22C>T
Haplotype 2 Polymorphism wt wt IVS2 -76_80del5 wt IVS4 -16A>G wt IVS6 -22C>T
Haplotype 3 -12G>A wt wt IVS4 +68A>G wt wt IVS6 -22C>T
wt wt wt wt wt wt IVS6 -22C>T
Mutations -30G>A wt wt wt wt wt wt
wt wt C172Y wt wt wt wt
wt wt wt wt wt D313Y wt
wt wt wt wt wt wt G395A
wt wt wt wt c.718_9 dellAA wt wt
wt wt D165H wt wt wt wt
Bono et al. BMC Research Notes 2011, 4:323
http://www.biomedcentral.com/1756-0500/4/323
Page 6 of 7GLA gene (-10 c>t, IVS2-76_80 del5, IVS4-16 A>G, IVS6-
22C>T) in four patients which is identical to the first of
the haplotypes mentioned above for our subjects [39]. The
-12 g>a, IVS4+68 A>G, IVS6-22C>T haplotype identified
in approximately 4% of our samples has not been reported
in the literature.
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